Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Childhood acute lymphoblastic leukaemia (ALL) with MLL rearrangement (MLL-r) is an aggressive disease still associated with a high mortality rate. Recent investigations have identified co-operating mutations in the RAS pathway and although the functional consequences of these mutations are not yet fully understood, aberrant regulation of RAS pathway signalling at both transcriptional and protein levels is observed. Studies investigating the efficacy of specific inhibitors of this pathway, e.g. MEK-inhibitors, have also achieved encouraging results. In this context, this mini-review summarizes the available data surrounding MLL-r infant ALL with RAS mutation in relation to other well-known features of this intriguing disease.

Original publication




Journal article


Biochim Biophys Acta Rev Cancer

Publication Date





521 - 526


Acute lymphoblastic leukaemia, MLL, Prognosis, RAS, Targeted therapy, Gene Rearrangement, Genes, ras, Histone-Lysine N-Methyltransferase, Humans, Mitogen-Activated Protein Kinase Kinases, Mutation, Myeloid-Lymphoid Leukemia Protein, Precursor Cell Lymphoblastic Leukemia-Lymphoma, fms-Like Tyrosine Kinase 3